{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:40:21Z","timestamp":1793904021810,"version":"4.8.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Scaling up overdose education and naloxone distribution (OEND), an evidence-based practice for reducing opioid overdose mortality, in communities remains a challenge. Novel models and intentional implementation strategies are needed. Drawing upon the EPIS model\u2019s phases of Exploration, Preparation, Implementation, and Sustainment (Aarons et al. in Adm Policy Ment Health 38:4\u201323, 2011), this paper describes the development of the University of Kentucky\u2019s unique centralized \u201cNaloxone Hub with Many Spokes\u201d approach to implementing OEND as part of the HEALing Communities Study (HCS-KY).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To scale up OEND in eight Kentucky counties, implementation strategies were utilized at two levels: a centralized university-based naloxone dispensing unit (\u201cNaloxone Hub\u201d) and adopting organizations (\u201cMany Spokes\u201d). Implementation strategies varied across the EPIS phases, but heavily emphasized implementation facilitation. The Naloxone Hub provided technical assistance, overdose education resources, and no-cost naloxone to partner organizations. Implementation outcomes across the EPIS phases were measured using data from internal study management trackers and naloxone distribution data submitted by partner organizations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 209 organizations identified as potential partners, 84.7% (n\u2009=\u2009177) engaged in the Exploration\/Preparation phase by participating in an initial meeting with an Implementation Facilitator about the HCS-KY OEND program. Adoption of the HCS-KY OEND program, defined as receipt of at least one shipment of naloxone, was achieved with 69.4% (n\u2009=\u2009145) of all organizations contacted. During the Implementation phase, partner organizations distributed 40,822 units of naloxone, with partner organizations distributing a mean of 281.5 units of naloxone (SD\u2009=\u2009806.2). The mean number of units distributed per county was 5102.8 (SD\u2009=\u20093653.3; range\u2009=\u20091057\u2009\u2212\u200911,053) and the mean county level distribution rate was 8396.5 units per 100,000 residents (SD\u2009=\u20098103.1; range\u2009=\u20091709.5\u201325,296.3). Of the partner organizations that adopted the HCS-KY OEND program, 87.6% (n\u2009=\u2009127) attended a sustainability meeting with an Implementation Facilitator and agreed to transition to the state-funded naloxone program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These data demonstrate the feasibility of this \u201cHub with Many Spokes\u201d model for scaling up OEND in communities highly affected by the opioid epidemic.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov, NCT04111939. Registered 30 September 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04111939\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04111939<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00426-6","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:02:02Z","timestamp":1701313322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Scaling up overdose education and naloxone distribution in Kentucky: adoption and reach achieved through a \u201chub with many spokes\u201d model"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct04111939","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0137-9337","authenticated-orcid":false,"given":"Hannah K.","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Oyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie B.","family":"Oser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"426_CR1","first-page":"1","volume":"457","author":"MR Spencer","year":"2022","unstructured":"Spencer MR, Minino AM, Warner M. Drug overdose deaths in the United States, 2001\u20132021. NCHS Data Brief. 2022;457:1\u20138.","journal-title":"NCHS Data Brief"},{"key":"426_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350","volume":"218","author":"C Florence","year":"2021","unstructured":"Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218: 108350. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108350.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR3","doi-asserted-by":"publisher","first-page":"e2116391","DOI":"10.1001\/jamanetworkopen.2021.16391","volume":"4","author":"S Slavova","year":"2021","unstructured":"Slavova S, Quesinberry D, Hargrove S, Rock P, Brancato C, Freeman PR, Walsh SL. Trends in drug overdose mortality rates in Kentucky, 2019\u20132020. JAMA Netw Open. 2021;4:e2116391. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.16391.","journal-title":"JAMA Netw Open"},{"key":"426_CR4","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Drug overdose mortality by state. https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm. Accessed 5 Oct 2023."},{"key":"426_CR5","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital statistics system, mortality 2018\u20132021 on CDC WONDER online database. http:\/\/wonder.cdc.gov\/mcd-icd10-expanded.html. Accesed 27 Mar 2023."},{"key":"426_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","volume":"111","author":"J Friedman","year":"2021","unstructured":"Friedman J, Akre S. COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January\u2013July 2020. Am J Public Health. 2021;111:1284\u201391. https:\/\/doi.org\/10.2105\/AJPH.2021.306256.","journal-title":"Am J Public Health"},{"key":"426_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109505","volume":"237","author":"JD Jones","year":"2022","unstructured":"Jones JD, Campbell AN, Brandt L, Metz VE, Martinez S, Wall M, Corbeil T, Andrews H, Castillo F, Neale J, et al. A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder. Drug Alcohol Depend. 2022;237: 109505. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109505.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111:1177\u201387. https:\/\/doi.org\/10.1111\/add.13326.","journal-title":"Addiction"},{"key":"426_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","volume":"8","author":"AK Clark","year":"2014","unstructured":"Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8:153\u201363. https:\/\/doi.org\/10.1097\/ADM.0000000000000034.","journal-title":"J Addict Med"},{"key":"426_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2021.306306","volume":"111","author":"A Razaghizad","year":"2021","unstructured":"Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, Kimmelman J, Martel MO, Eisenberg MJ. The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews. Am J Public Health. 2021;111:e1\u201312. https:\/\/doi.org\/10.2105\/AJPH.2021.306306.","journal-title":"Am J Public Health"},{"key":"426_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109555","volume":"238","author":"LM Holmes","year":"2022","unstructured":"Holmes LM, Rishworth A, King BH. Disparities in opioid overdose survival and naloxone administration in Pennsylvania. Drug Alcohol Depend. 2022;238: 109555. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109555.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.drugpo.2013.05.006","volume":"25","author":"JD Jones","year":"2014","unstructured":"Jones JD, Roux P, Stancliff S, Matthews W, Comer SD. Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. Int J Drug Policy. 2014;25:166\u201370. https:\/\/doi.org\/10.1016\/j.drugpo.2013.05.006.","journal-title":"Int J Drug Policy"},{"key":"426_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103513","volume":"100","author":"WC Tse","year":"2022","unstructured":"Tse WC, Djordjevic F, Borja V, Picco L, Lam T, Olsen A, Larney S, Dietze P, Nielsen S. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a \u2018moral hazard\u2019 associated with naloxone supply. Int J Drug Policy. 2022;100: 103513. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103513.","journal-title":"Int J Drug Policy"},{"key":"426_CR14","doi-asserted-by":"publisher","first-page":"107536","DOI":"10.1016\/j.drugalcdep.2019.06.038","volume":"204","author":"RB Naumann","year":"2019","unstructured":"Naumann RB, Durrance CP, Ranapurwala SI, Austin AE, Proescholdbell S, Childs R, Marshall SW, Kansagra S, Shanahan ME. Impact of a community-based naloxone distribution program on opioid overdose death rates. Drug Alcohol Depend. 2019;204:107536. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.06.038.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346: f174. https:\/\/doi.org\/10.1136\/bmj.f174.","journal-title":"BMJ"},{"key":"426_CR16","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/add.14664","volume":"114","author":"MA Irvine","year":"2019","unstructured":"Irvine MA, Kuo M, Buxton JA, Balshaw R, Otterstatter M, Macdougall L, Milloy MJ, Bharmal A, Henry B, Tyndall M, et al. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Addiction. 2019;114:1602\u201313. https:\/\/doi.org\/10.1111\/add.14664.","journal-title":"Addiction"},{"key":"426_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2021.100031","author":"IJ Rao","year":"2021","unstructured":"Rao IJ, Humphreys K, Brandeau ML. Effectiveness of policies for addressing the US opioid epidemic: a model-based analysis from the Stanford-Lancet Commission on the North American Opioid Crisis. Lancet Reg Health Am. 2021. https:\/\/doi.org\/10.1016\/j.lana.2021.100031.","journal-title":"Lancet Reg Health Am"},{"key":"426_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","volume":"108","author":"AL Pitt","year":"2018","unstructured":"Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018;108:1394\u2013400. https:\/\/doi.org\/10.2105\/AJPH.2018.304590.","journal-title":"Am J Public Health"},{"key":"426_CR19","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2468-2667(21)00304-2","volume":"7","author":"MA Irvine","year":"2022","unstructured":"Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, Doe-Simkins M, Walley AY, Marshall BDL, Bratberg J, Green TC. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022;7:e210\u20138. https:\/\/doi.org\/10.1016\/S2468-2667(21)00304-2.","journal-title":"Lancet Public Health"},{"key":"426_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6933a2","volume":"69","author":"BH Lambdin","year":"2020","unstructured":"Lambdin BH, Bluthenthal RN, Wenger LD, Wheeler E, Garner B, Lakosky P, Kral AH. Overdose education and naloxone distribution within syringe service programs\u2014United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:1117\u201321. https:\/\/doi.org\/10.15585\/mmwr.mm6933a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"426_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109518","volume":"237","author":"LG Hill","year":"2022","unstructured":"Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky VS, et al. Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 2022;237: 109518. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109518.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ajem.2021.03.056","volume":"47","author":"AS Kilaru","year":"2021","unstructured":"Kilaru AS, Liu M, Gupta R, Perrone J, Delgado MK, Meisel ZF, Lowenstein M. Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal. Am J Emerg Med. 2021;47:154\u20137. https:\/\/doi.org\/10.1016\/j.ajem.2021.03.056.","journal-title":"Am J Emerg Med"},{"key":"426_CR23","doi-asserted-by":"publisher","first-page":"e200117","DOI":"10.1001\/jamanetworkopen.2020.0117","volume":"3","author":"JG Katzman","year":"2020","unstructured":"Katzman JG, Takeda MY, Greenberg N, Moya Balasch M, Alchbli A, Katzman WG, Salvador JG, Bhatt SR. Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program. JAMA Netw Open. 2020;3:e200117. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0117.","journal-title":"JAMA Netw Open"},{"key":"426_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1186\/s12889-022-13298-3","volume":"22","author":"J Agley","year":"2022","unstructured":"Agley J, Xiao Y, Eldridge L, Meyerson B, Golzarri-Arroyo L. Beliefs and misperceptions about naloxone and overdose among U.S. laypersons: a cross-sectional study. BMC Public Health. 2022;22:924. https:\/\/doi.org\/10.1186\/s12889-022-13298-3.","journal-title":"BMC Public Health"},{"key":"426_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.drugalcdep.2017.05.001","volume":"178","author":"R McDonald","year":"2017","unstructured":"McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-conception and maturation. Drug Alcohol Depend. 2017;178:176\u201387. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.05.001.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/S10488-010-0327-7","volume":"38","author":"GA Aarons","year":"2011","unstructured":"Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based practice implementation in public service sectors. Adm Policy Ment Health. 2011;38:4\u201323. https:\/\/doi.org\/10.1007\/S10488-010-0327-7.","journal-title":"Adm Policy Ment Health"},{"key":"426_CR27","first-page":"228","volume":"34","author":"AC Feldstein","year":"2008","unstructured":"Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Joint Comm J Qual Patient Saf. 2008;34:228\u201343.","journal-title":"Joint Comm J Qual Patient Saf"},{"key":"426_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-1184-1150","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. https:\/\/doi.org\/10.1186\/1748-5908-1184-1150.","journal-title":"Implement Sci"},{"key":"426_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17:75. https:\/\/doi.org\/10.1186\/s13012-022-01245-0.","journal-title":"Implement Sci"},{"key":"426_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/S10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Mental Health Mental Health Serv Res. 2011;38:65\u201376. https:\/\/doi.org\/10.1007\/S10488-010-0319-7.","journal-title":"Adm Policy Mental Health Mental Health Serv Res"},{"key":"426_CR31","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/ajph.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89:1322\u20137. https:\/\/doi.org\/10.2105\/ajph.89.9.1322.","journal-title":"Am J Public Health"},{"key":"426_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13012-015-0209-1","volume":"10","author":"BJ Powell","year":"2015","unstructured":"Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, Proctor EK, Kirchner JE. A refined compilation of implementation strategies: results from the expert recommendations for implementing change (ERIC) project. Implement Sci. 2015;10:21. https:\/\/doi.org\/10.1186\/s13012-015-0209-1.","journal-title":"Implement Sci"},{"key":"426_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1077558711430690","volume":"69","author":"BJ Powell","year":"2012","unstructured":"Powell BJ, McMillen JC, Proctor EK, Carpenter CR, Griffey RT, Bunger AC, Glass JE, York JL. A compilation of strategies for implementing clinical innovations in health and mental health. Med Care Res Rev. 2012;69:123\u201357.","journal-title":"Med Care Res Rev"},{"key":"426_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/08897077.2015.1132294","volume":"37","author":"EL Winstanley","year":"2016","unstructured":"Winstanley EL, Clark A, Feinberg J, Wilder CM. Barriers to implementation of opioid overdose prevention programs in Ohio. Subst Abus. 2016;37:42\u20136. https:\/\/doi.org\/10.1080\/08897077.2015.1132294.","journal-title":"Subst Abus"},{"key":"426_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.annemergmed.2020.02.013","volume":"76","author":"V Eswaran","year":"2020","unstructured":"Eswaran V, Allen KC, Bottari DC, Splawski JA, Bains S, Aks SE, Swoboda HD, Moore PQ, Tran TH, Salisbury-Afshar E, et al. Take-home naloxone program implementation: lessons learned from seven Chicago-area hospitals. Ann Emerg Med. 2020;76:318\u201327. https:\/\/doi.org\/10.1016\/j.annemergmed.2020.02.013.","journal-title":"Ann Emerg Med"},{"key":"426_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13104-016-2268-z","volume":"9","author":"ML Drainoni","year":"2016","unstructured":"Drainoni ML, Koppelman EA, Feldman JA, Walley AY, Mitchell PM, Ellison J, Bernstein E. Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. BMC Res Notes. 2016;9:465. https:\/\/doi.org\/10.1186\/s13104-016-2268-z.","journal-title":"BMC Res Notes"},{"key":"426_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/ADM.0000000000000672","volume":"15","author":"AL Hincapie","year":"2021","unstructured":"Hincapie AL, Hegener M, Heaton PC, Fish G, Fetters K, Sneed GT, Koechlin K, DeFiore-Hyrmer J, Holthusen A, MacKinnon NJ. Challenges and facilitators of implementing a physician-approved naloxone protocol: a mixed-methods study. J Addict Med. 2021;15:40\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000000672.","journal-title":"J Addict Med"},{"key":"426_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/injuryprev-2020-043666","volume":"27","author":"TM Rudisill","year":"2021","unstructured":"Rudisill TM, Ashraf AJ, Linn HI, Sayres S, Jeffries JE, Gurka KK. Facilitators, barriers and lessons learnt from the first state-wide naloxone distribution conducted in West Virginia. Inj Prev. 2021;27:369\u201374. https:\/\/doi.org\/10.1136\/injuryprev-2020-043666.","journal-title":"Inj Prev"},{"key":"426_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12954-020-00375-2","volume":"17","author":"JG Salvador","year":"2020","unstructured":"Salvador JG, Sussman AL, Takeda MY, Katzman WG, Moya Balasch M, Katzman JG. Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico. Harm Reduct J. 2020;17:31. https:\/\/doi.org\/10.1186\/s12954-020-00375-2.","journal-title":"Harm Reduct J"},{"issue":"57","key":"426_CR40","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1016\/j.japh.2017.01.002","volume":"2017","author":"J Devries","year":"2003","unstructured":"Devries J, Rafie S, Polston G. Implementing an overdose education and naloxone distribution program in a health system. J Am Pharm Assoc. 2003;2017(57):S154\u201360. https:\/\/doi.org\/10.1016\/j.japh.2017.01.002.","journal-title":"J Am Pharm Assoc"},{"key":"426_CR41","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1016\/j.japh.2017.01.022","volume":"57","author":"EM Oliva","year":"2017","unstructured":"Oliva EM, Christopher MLD, Wells D, Bounthavong M, Harvey M, Himstreet J, Emmendorfer T, Valentino M, Franchi M, Goodman F, et al. Opioid overdose education and naloxone distribution: development of the Veterans Health Administration\u2019s national program. J Am Pharm Assoc. 2017;57:S168-S179.e164. https:\/\/doi.org\/10.1016\/j.japh.2017.01.022.","journal-title":"J Am Pharm Assoc"},{"issue":"57","key":"426_CR42","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.japh.2016.11.003","volume":"2017","author":"M Bounthavong","year":"2003","unstructured":"Bounthavong M, Harvey MA, Wells DL, Popish SJ, Himstreet J, Oliva EM, Kay CL, Lau MK, Randeria-Noor PP, Phillips AG, Christopher MLD. Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: a preliminary analysis. J Am Pharm Assoc. 2003;2017(57):S68\u201372. https:\/\/doi.org\/10.1016\/j.japh.2016.11.003.","journal-title":"J Am Pharm Assoc"},{"key":"426_CR43","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.17269\/cjph.108.5989","volume":"108","author":"LK Freeman","year":"2017","unstructured":"Freeman LK, Bourque S, Etches N, Goodison K, O\u2019Gorman C, Rittenbach K, Sikora CA, Yarema M. Alberta\u2019s provincial take-home naloxone program: a multi-sectoral and multi-jurisdictional response to overdose. Can J Public Health. 2017;108:e398\u2013402. https:\/\/doi.org\/10.17269\/cjph.108.5989.","journal-title":"Can J Public Health"},{"key":"426_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugalcdep.2016.12.013","volume":"173","author":"D Madah-Amiri","year":"2017","unstructured":"Madah-Amiri D, Clausen T, Lobmaier P. Rapid widespread distribution of intranasal naloxone for overdose prevention. Drug Alcohol Depend. 2017;173:17\u201323. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.12.013.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.drugalcdep.2016.04.007","volume":"163","author":"D Madah-Amiri","year":"2016","unstructured":"Madah-Amiri D, Clausen T, Lobmaier P. Utilizing a train-the-trainer model for multi-site naloxone distribution programs. Drug Alcohol Depend. 2016;163:153\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.04.007.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ypmed.2015.04.002","volume":"80","author":"TA Simpatico","year":"2015","unstructured":"Simpatico TA. Vermont responds to its opioid crisis. Prev Med. 2015;80:10\u20131. https:\/\/doi.org\/10.1016\/j.ypmed.2015.04.002.","journal-title":"Prev Med"},{"key":"426_CR47","doi-asserted-by":"publisher","first-page":"108335","DOI":"10.1016\/j.drugalcdep.2020.108335","volume":"217","author":"HEALing Communities Study Consortium","year":"2020","unstructured":"HEALing Communities Study Consortium. The HEALing (helping to End Addiction Long-Term SM) Communities Study: protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug Alcohol Depend. 2020;217:108335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108335.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108326","volume":"217","author":"L Sprague Martinez","year":"2020","unstructured":"Sprague Martinez L, Rapkin BD, Young A, Freisthler B, Glasgow L, Hunt T, Salsberry PJ, Oga EA, Bennet-Fallin A, Plouck TJ, et al. Community engagement to implement evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217: 108326. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108326.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108325","volume":"217","author":"T Winhusen","year":"2020","unstructured":"Winhusen T, Walley A, Fanucchi LC, Hunt T, Lyons M, Lofwall M, Brown JL, Freeman PR, Nunes E, Beers D, et al. The opioid-overdose reduction continuum of care approach (ORCCA): evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217: 108325. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108325.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059328","volume":"12","author":"AM Young","year":"2022","unstructured":"Young AM, Brown JL, Hunt T, Sprague Martinez LS, Chandler R, Oga E, Winhusen TJ, Baker T, Battaglia T, Bowers-Sword R, et al. Protocol for community-driven selection of strategies to implement evidence-based practices to reduce opioid overdoses in the HEALing Communities Study: a trial to evaluate a community-engaged intervention in Kentucky, Massachusetts, New York and Ohio. BMJ Open. 2022;12: e059328. https:\/\/doi.org\/10.1136\/bmjopen-2021-059328.","journal-title":"BMJ Open"},{"key":"426_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109804","volume":"245","author":"R Chandler","year":"2023","unstructured":"Chandler R, Nunes EV, Tan S, Freeman PR, Walley AY, Lofwall M, Oga E, Glasgow L, Brown JL, Fanucchi L, et al. Community selected strategies to reduce opioid-related overdose deaths in the HEALing (helping to End Addiction Long-Term (SM)) Communities Study. Drug Alcohol Depend. 2023;245: 109804. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.109804.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109710","volume":"242","author":"K Thompson","year":"2023","unstructured":"Thompson K, Barocas JA, Delcher C, Bae J, Hammerslag L, Wang J, Chandler R, Villani J, Walsh S, Talbert J. The prevalence of opioid use disorder in Kentucky\u2019s counties: a two-year multi-sample capture-recapture analysis. Drug Alcohol Depend. 2023;242: 109710. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109710.","journal-title":"Drug Alcohol Depend"},{"key":"426_CR53","first-page":"1","volume":"2","author":"DD Ingram","year":"2014","unstructured":"Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. Vital Health Stat. 2014;2:1\u201373.","journal-title":"Vital Health Stat"},{"key":"426_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108731","volume":"138","author":"ML Drainoni","year":"2022","unstructured":"Drainoni ML, Knudsen HK, Adams K, Andrews-Higgins SA, Auritt V, Back S, Barkowski LK, Batty EJ, Behrooz MR, Bell S, et al. Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention. J Subst Abuse Treat. 2022;138: 108731. https:\/\/doi.org\/10.1016\/j.jsat.2022.108731.","journal-title":"J Subst Abuse Treat"},{"key":"426_CR55","unstructured":"Kentucky revised statutes Food, Drug and Cosmetic Act. Statute 217.186. https:\/\/apps.legislature.ky.gov\/law\/statutes\/statute.aspx?id=52963."},{"key":"426_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100126","author":"RM Bohler","year":"2023","unstructured":"Bohler RM, Freeman PR, Villani J, Hunt T, Linas BS, Walley AY, Green TC, Lofwall MR, Bridden C, Frazier LA, et al. The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses. Drug Alcohol Depend Rep. 2023. https:\/\/doi.org\/10.1016\/j.dadr.2022.100126.","journal-title":"Drug Alcohol Depend Rep"},{"key":"426_CR57","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"426_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102872","volume":"83","author":"AB Collins","year":"2020","unstructured":"Collins AB, Ndoye CD, Arene-Morley D, Marshall BDL. Addressing co-occurring public health emergencies: the importance of naloxone distribution in the era of COVID-19. Int J Drug Policy. 2020;83: 102872. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102872.","journal-title":"Int J Drug Policy"},{"key":"426_CR59","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1007\/s10461-020-02886-2","volume":"24","author":"SN Glick","year":"2020","unstructured":"Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC. The impact of COVID-19 on syringe services programs in the United States. AIDS Behav. 2020;24:2466\u20138. https:\/\/doi.org\/10.1007\/s10461-020-02886-2.","journal-title":"AIDS Behav"},{"key":"426_CR60","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2105\/AJPH.2020.305707","volume":"110","author":"K Nowotny","year":"2020","unstructured":"Nowotny K, Bailey Z, Omori M, Brinkley-Rubinstein L. COVID-19 exposes need for progressive criminal justice reform. Am J Public Health. 2020;110:967\u20138. https:\/\/doi.org\/10.2105\/AJPH.2020.305707.","journal-title":"Am J Public Health"},{"key":"426_CR61","volume-title":"Regression models for categorical dependent variables using stata","author":"JS Long","year":"2014","unstructured":"Long JS, Freese J. Regression models for categorical dependent variables using stata. 3rd ed. College Station: StataCorp; 2014.","edition":"3"},{"key":"426_CR62","unstructured":"Census Bureau US. QuickFacts. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045222. Accessed 30 Mar 2023."},{"key":"426_CR63","doi-asserted-by":"publisher","first-page":"e2037259","DOI":"10.1001\/jamanetworkopen.2020.37259","volume":"4","author":"BP Linas","year":"2021","unstructured":"Linas BP, Savinkina A, Madushani R, Wang J, Eftekhari Yazdi G, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, et al. Projected estimates of opioid mortality after community-level interventions. JAMA Netw Open. 2021;4:e2037259. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37259.","journal-title":"JAMA Netw Open"},{"key":"426_CR64","unstructured":"Oyler DR, Knudsen HK, Oser CB, Walsh SL, Roberts M, Nigam SR, Westgate P, Watson J, Freeman PR. Equity of overdose education and naloxone distribution provided in the Kentucky HEALing Communities Study. Drug Alc Depend Rep. in press"},{"key":"426_CR65","unstructured":"US Food & Drug Administration. FDA approves first over-the-counter naloxone nasal spray. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray. Accessed 30 Mar 2023."},{"key":"426_CR66","doi-asserted-by":"publisher","first-page":"558","DOI":"10.2105\/AJPH.2021.306699","volume":"112","author":"R Jawa","year":"2022","unstructured":"Jawa R, Murray S, Tori M, Bratberg J, Walley A. Federal policymakers should urgently and greatly expand naloxone access. Am J Public Health. 2022;112:558\u201361. https:\/\/doi.org\/10.2105\/AJPH.2021.306699.","journal-title":"Am J Public Health"},{"key":"426_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2019.105932","volume":"130","author":"CS Davis","year":"2020","unstructured":"Davis CS, Carr D. Over the counter naloxone needed to save lives in the United States. Prev Med. 2020;130: 105932. https:\/\/doi.org\/10.1016\/j.ypmed.2019.105932.","journal-title":"Prev Med"},{"key":"426_CR68","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/1475-6773.13125","volume":"54","author":"SM Murphy","year":"2019","unstructured":"Murphy SM, Morgan JR, Jeng PJ, Schackman BR. Will converting naloxone to over-the-counter status increase pharmacy sales? Health Serv Res. 2019;54:764\u201372. https:\/\/doi.org\/10.1111\/1475-6773.13125.","journal-title":"Health Serv Res"},{"key":"426_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/IPRP.S244709","volume":"10","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Hill LG, Davis CS. Considering the potential benefits of over-the-counter naloxone. Integr Pharm Res Pract. 2021;10:13\u201321. https:\/\/doi.org\/10.2147\/IPRP.S244709.","journal-title":"Integr Pharm Res Pract"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00426-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:06:56Z","timestamp":1701313616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00426-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00426-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. All partner organizations agreed to provide anonymous data on naloxone distribution as part of the standing order agreement.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HKK, PRF, DRO, and CBO declare that they have no competing interests. SLW has served as a scientific advisor\/consultant for Opiant Pharmaceuticals and Pocket Naloxone.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}